ICD 10 CM E10.3319 | Description & Clinical Information

ICD 10 E10.3319 describes a chronic autoimmune disease that results from the destruction of pancreatic beta cells, leading to insufficient insulin production and subsequent high blood glucose levels, which in turn slowly damages the blood supply to the retina with moderate growth of new blood vessels and macular edema, and while the provider does not specify which eye is affected, this code is used to report DM type 1 with moderate NPDR and macular edema of an unspecified eye.

Official Description Of E10.3319

The ICD 10 CM book defines ICD 10 code E10.3319 as:

When To Use E10.3319

The diagnosis described by ICD 10 CM E10.3319 is a medical condition that affects the eyes of patients suffering from Type 1 diabetes mellitus. Known as Nonproliferative Diabetic Retinopathy (NPDR), the condition is characterized by the presence of lesions in the retina. These lesions include microaneurysms, small dot and blot hemorrhages, splinter hemorrhages, and intraretinal microvascular abnormalities (IRMA). The severity of the lesions determines the degree of severity of the disease, which can be classified as mild, moderate, or severe.

In moderate NPDR, there may be severe dot hemorrhage and microaneurysms present in one to three quadrants. The macula, which is the point of sharpest vision on the retina, can also be affected by the condition. Macular edema, which is the accumulation of fluid in the macula due to leaking blood vessels, can result in blurred vision, cotton wool spots, and swelling of the macula. Patients may also experience other symptoms such as dark spots, rings, pain and pressure in the eyes, poor vision, and light flashes.

This condition can cause vision loss if left untreated. Patients may also experience dizziness, fatigue, nausea, excessive thirst (polydipsia), frequent urination (polyuria), increased hunger (polyphagia), and unintentional weight loss, among other symptoms.

Diagnosis of NPDR is typically made through a combination of history, physical examination, and eye tests. These tests may include ophthalmoscopy, tonometry, fundus photography, optical coherence tomography, fluorescein or indocyanine green angiography, and B-scan ultrasonography.

Patients with Type 1 diabetes mellitus may also require a number of diagnostic tests before treatment begins. These tests include glucose tolerance tests, plasma glucose levels, HbA1c levels, CBC, urine for albumin, glucose, and ketones, and anti-insulin antibodies.

Treatment for NPDR may include laser photocoagulation, vitrectomy, and anti-VEGF or steroid injections. Laser photocoagulation is a treatment that uses lasers to treat leaking blood vessels in the retina. Vitrectomy is a surgical procedure that removes the vitreous gel from the eye. Anti-VEGF or steroid injections can help reduce inflammation.

For patients with Type 1 diabetes, the recommended treatment involves lifelong insulin therapy, diet management, and regular blood glucose monitoring. Patients are advised to monitor their blood glucose levels using fingerstick monitors or continuous glucose monitoring devices. This helps patients with difficult-to-manage diabetes to maintain good blood glucose control. Some patients may require insulin pumps to regulate their blood sugar levels.

In conclusion, ICD 10 CM E10.3319 is a code that describes Nonproliferative Diabetic Retinopathy in patients with Type 1 diabetes. The disease can lead to vision loss if left untreated, but proper diagnosis and treatment can help prevent this from happening. Regular monitoring of blood glucose levels is essential for managing diabetes and treating its associated complications.